D5290C00004-A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
To determine if the study vaccine administered to healthy infants entering their first RSV season, in reducing lower respiratory tract infection due to confirmed RSV.